TrialFrontiers in endocrinology2025

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial.

Takeshi Osonoi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.